Transaction · 0000874015-26-000098

HOUGEN ELIZABETH L

HOUGEN ELIZABETH L, EVP, CFO, reported an open-market or private sale at IONIS PHARMACEUTICALS INC involving 6988.000000 shares for an estimated $581702.08. Reported holdings after the transaction were 132881.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SEVP, CFO
IONSIONIS PHARMACEUTICALS INC
Filing timeFeb 03
Trade dateJan 30, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$83.07
Pre-filing
1mo ago -1.3%1w ago -4.1%1d ago -4.1%
Returns since
7d +0.0%30d -1.3%90d -9.4%180d -37.7%1y -26.5%

IONS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
IONS since 2026-02-03Filed 218 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000874015-26-000098
Common Stock
Transaction date
Jan 30, 2026
Filed Feb 03, 2026, 01:51 AM · 4d delay
Shares
6.98k sh
$8.32k per share
Estimated value
-$58.1M
Computed from shares × price
Holdings after
132k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership
+6score
Filing-only score

+6

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP, Finance & CFO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compen…

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.11 to $83.32 inclusive. The reporting person undertakes to provi…

Original filing · 0000874015-26-000098
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

IONS